The Oklahoma Medical Research Foundation's ten-year COBRE, """"""""Science in a Culture of Mentoring (RR15577) has been transformative in providing the foundation for growth in Immunology research in our state. This COBRE provided mentoring and support to launch 12 independent research careers and the infrastructure has led to 10 """"""""non NCRR NIH institutes"""""""" program or center grants as a direct result of this funding. OMRF and Oklahoma can now legitimately claim to be a """"""""Center"""""""" for Immunology in the United States. Now, 16 COBRE eligible investigators present projects to be supported by mentoring and critical Core support. We have found that Mentoring and Core support is fundamental to our success. The Human Monoclonal Antibody (hmAb) Core grows out of COBRE supported scientific observations (Nature 2008), which allow rapid production of hmAbs after vaccination. With over 300 hmAbs already produced and many projects waiting, this Core is poised to provide unique research tools that should allow our COBRE Investigators to make major advances. The Serum Analyte and Biomarker Core expands on OMRF's strengths in human autoantibody detection, cytokine/chemokine measurements, epitope mapping and serum analyte development. It will provide access to the centralized generation of quality controlled data to assist projects in autoimmunity, gene-environment interactions, and human immune responses. The Immunophenotyping Core applies new whole blood multiparameter testing of detailed subsets of B cells, T cells, and other cell types. This Core provides centralized SOPs, tested reagents and experimental designs for complex human disease questions in many immunology-based projects. Finally, the Clinical Core provides patient/control identification, recruitment, phenotype characterization and human subjects training to COBRE investigators, with all 17 proposed pilot projects requesting use of this Core. The Pilot Project Core will identify, support and mentor COBRE eligible junior scientists through one-year pilot projects. Extremely productive in prior years, 17 applications were received for this cycle. We view these pilot funds as fundamental to our plans for the future of our Immunology focus in Oklahoma. The Administrative Core will provide mentoring teams and administrative support to 16 COBRE eligible junior scientists, implement and expand multidisciplinary enrichment programs, support collaborations between Oklahoma investigators, evaluate and manage the effectiveness of pilot projects. We are confident that with these additional funds OMRF and Oklahoma can have an outstanding Center of Immunology Excellence.
(provided by applicant): This OMRF COBRE has led to an explosive expansion in Immunology based, clinically relevant research in Oklahoma. Through outside recruits and development of local junior scientists, this funding mechanism has resulted in exciting new discoveries in vaccine immunology, autoimmunity, Alzheimer's'research and other complex human diseases. Transition of this productive COBRE to a Cores Center will help launch additional new investigative careers and facilitate additional Program support, from a variety of other national agencies.
|Waubant, Emmanuelle; Mowry, Ellen M; Krupp, Lauren et al. (2013) Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler 19:891-5|
|Koelsch, Kristi A; Webb, Ryan; Jeffries, Matlock et al. (2013) Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J Autoimmun 41:168-74|
|Smith, Kenneth; Muther, Jennifer J; Duke, Angie L et al. (2013) Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. Immunobiology 218:745-54|
|Cogman, Abigail R; Chakravarty, Eliza F (2013) The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine 31:3640-3|
|Ramos, Paula S; Oates, James C; Kamen, Diane L et al. (2013) Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol 40:842-9|
|Lessard, Christopher J; Adrianto, Indra; Ice, John A et al. (2012) Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet 90:648-60|
|Wang, S; Adrianto, I; Wiley, G B et al. (2012) A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun 13:380-7|
|Adrianto, Indra; Wang, Shaofeng; Wiley, Graham B et al. (2012) Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum 64:3695-705|
|James, Judith A; Robertson, Julie M (2012) Lupus and Epstein-Barr. Curr Opin Rheumatol 24:383-8|
|Niewold, Timothy B; Kelly, Jennifer A; Kariuki, Silvia N et al. (2012) IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 71:463-8|
Showing the most recent 10 out of 46 publications